MedTrace Logo

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NCT05605613 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-11-09

No results posted yet for this study

Summary

This is a randomized controlled trial to determine the efficacy and safety of PD-1 Antibody in addition to Bronchial Arterial Chemoembolization in stage III-Ⅳ NSCLC patients who failed, refused or ineligible to receive standard treatments.

Conditions

Interventions

DRUG

PD-1 Antibody

PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1

DEVICE

BACE

Bronchial Arterial Chemoembolization

Sponsors & Collaborators

  • Xuhua Duan

    lead OTHER

Principal Investigators

  • Xuhua Duan · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-29
Primary Completion
2023-11-15
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05605613 on ClinicalTrials.gov